Loading clinical trials...
Loading clinical trials...
A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Conditions
Interventions
H3B-6545
Locations
39
United States
Western Regional Medical Center, Inc., DBA Cancer Treatment Centers of America, Phoenix
Goodyear, Arizona, United States
University of California Los Angeles
Los Angeles, California, United States
University of California San Francisco
San Francisco, California, United States
University of Colorado - Cancer Center
Aurora, Colorado, United States
Holy Cross Hospital Inc
Fort Lauderdale, Florida, United States
Florida Cancer Specialists South
Fort Myers, Florida, United States
Start Date
August 23, 2017
Primary Completion Date
October 26, 2023
Completion Date
October 26, 2023
Last Updated
February 25, 2025
NCT05468034
NCT04541381
NCT03137095
NCT07547774
NCT04852887
NCT06393374
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions